SOLIAIR™: Company Presentation Slide Show (PowerPoint)!
Dear Drug Discovery and Healthcare Investors, I would like to introduce to you my Dietary Supplement for Respiratory and Chronic Lung Diseases! I believe my product has great potential and a huge market. I would like to explore the possibility of cooperation with you and your company and would appreciate your response! SOLIAIR™ Product Overview: SOLIAIR™ is a blend of botanical extracts and a food supplement that contains a unique composition of ingredients, which has reported beneficial impact. SOLIAIR™ can contribute to strengthening the respiratory system and may help patients in chronic respiratory diseases such as Obstructive Lung Disease, Asthma, Bronchitis, COPD (Chronic Obstructive Pulmonary Disease) and other respiratory infections. Patients taking SOLIAIR™ reported a decrease in seasonal infections of the respiratory tract. Reducing the incidence of respiratory infections benefit tremendous potential. The SOLIAIR™ food supplement is free of side effects and has no interaction with conventional medication used for treatment of respiratory disorders! Each SOLIAIR™ food supplement has been authorized and defined by the Israeli Ministry of Health and according to Pharmacists Regulation. The SOLIAIR™ has a patent pending! Solomon Jacob Profile: At the age of 69, the inventor (Solomon Jacob) was diagnosed with a chronic inflammatory condition of the lungs, possibly COPD. Solomon realized that COPD is a complex disease and a treatment will have to address several distinct aspects of the disease, possibly by using a complex mixture of plant extracts. Knowing the steroids side-effects, Solomon decided to develop a herbal composition and treat himself with it. Solomon found a composition that was very effective and within a short period of time, his lab test returned showing an unusual improvement! Market Size Overview: COPD (Chronic Obstructive Pulmonary Disease), Bronchitis and Asthma are Common Diseases and Has No Cure Yet! Respiratory Infections are an important factor and increase the mortality of these diseases. It is estimated that 340 million people worldwide suffer from this disease. Therapy costs for COPD and its complications totaled in 2006 at $176.8 billion and are expected to rise to $427.6 billion by 2017 and to $832.9 billion by 2021! The SOLIAIR™ Company Is Looking for a Person or a Company That: - 1. Will commercialize the product. - 2. Handle all the certification to sell the product. - 3. Sell/Export the product worldwide. * Direct Sales or Franchise Priority! Please Contact SOLIAIR™ Team for More Information: Name: Solomon Jacob (Inventor & Director) e-Mail: solomonj40@gmail.com Company Address: Haifa, 34753 Israel Phone: +972-(0)54-729-5023 LinkedIn Company Profile: goo.gl/tAokA1 Best Regards, SOLIAIR™ Team
Recommended
More Related Content
Recently uploaded
Recently uploaded (20)
Featured
Featured (20)
SOLIAIR™: Company Presentation Slide Show (PowerPoint)!
- 1. AUGUST 2012
- 2. PRODUCT DESCRIPTION Is a blend of dry botanical extracts, mixed in honey and date syrup. Each botanical extract has been authorized and defined by the Israeli Ministry of Health and according to Pharmacists Regulation. The Soliair™ has a patent pending
- 3. is a food supplement that contains a unique composition of ingredients, which has reported beneficial impact: 1. Honey - with antioxidant and antimicrobial effects. 2. 8 dried botanical extracts with antiinflammatory and antioxidant effects, along with potentiation of the immune system
- 4. PRODUCT BENEFITS can contribute to strengthening the respiratory system and may help patients in chronic respiratory diseases such as obstructive lung disease: COPD (chronic obstructive Disease of the airways usually caused by smoking) Asthma Bronchiectasis
- 5. Market Size and Potential COPD and asthma are common diseases: 5% of Americans over the age of 18 and 5-10% of Israelis are suffering or will suffer from COPD. It is estimated that 340 million people worldwide suffer from this disease. Estimates show that in Israel 2% of adults suffer from asthma. In the U.S. incidence of the disease in adults is close to 8%.
- 6. The Potential Therapy costs for COPD and its complications totaled in 2006 at $176.8 billion and are expected to rise to $389.2 billion by 2011 and to $832.9 billion by 2021
- 7. The Potential cont. Patients taking reported a decrease in seasonal infections of the respiratory tract . Reducing the incidence of respiratory infections benefit tremendous potential: Respiratory infections are an important factor in worsening the clinical course of chronic lung disease and increase the mortality of these diseases.
- 8. The Potential cont. Respiratory infections, including seasonal flu also damage the healthy young population; and has serious economic damage bearings due to absenteeism from work and school and a cause for hospital admissions.
- 9. Conventional drug therapy for Obstructive lung diseases Current maintenance therapy includes a variety of medications taken (through inhalers); - Steroid drugs, which may cause local side effects (oral candidiasis, hoarseness) and in high doses - adverse systemic side effects. - Bronchodilators
- 10. Conventional drug therapy for Obstructive lung diseases During exacerbation events of COPD systemic administration of steroids is common. Such therapy carries significant side effects, such as salt retention and blood sugar elevation.
- 11. The Situation Today Conventional drug therapy 1. Has limited efficacy in patients with asthma and can not significantly inhibit the deterioration of respiratory function in patients with COPD and does not reduce disease exacerbations, hospitalization and mortality. 2. Causes side effects 3. Is expensive
- 12. As far as we know, the supplement is free of side effects and has no interaction with conventional medication used for treatment of respiratory disorders.
- 13. מדגם של 5 מטופלים טפול תרופתי מגדר מטופל משך גיל אבחון המחלה המחלה זמן עד לשיפור מינון התוסף חודשים 2 כפיות 3 סטרואידים חמצן חודש 1 כפיות 3 משאף סטרואידי ילדות חודשים 3 כפיות 3 :משאפים מרחיבי סמפונות סטרואיד -+ שנים 2 COPD חודש 1 כפיות 3 משאף סטרואידי ילדות asthma שנים 3 BOOP 07 'נ 1 asthma 27 'ז 2 06 'ז 3 94 'נ 4 07 'ז 5 חודשים 3 כפיות 3 הוצע טפול בסטרואידים שנים3 Diffuse .lung dis גיל
- 14. תפקודי נשימה של מטופלת מספר 4 90/3/01 90/2/71
- 15. חזה מקבילים CTחתכי של מטופל מספר 5 )סולי( לפני ואחרי SOLIAIRנטילת אוקטובר 0102 מאי 8002
- 16. האחרונה של סולי CTפענוח בדיקת ה
- 17. ,מכתב תודה של אחת המטופלות של סולי SOLIAIRהמתאר שיפור במצבה לאחר נטילת
- 18. מכתב תודה נוסף
- 21. The Company is looking for a partner that Will commercialize the product Will team up with us to produce 2-3 applications Conduct a clinical research (if needed) Handle all the certification to sell the product Sell the product in Israel Export the product worldwide